On Monday, Pfizer Inc. (NYSE:PFE) released top-line safety and immunogenicity results from substudy B of the ongoing pivotal MONeT Phase 3 trial, evaluating two doses of Abrysvo vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus-associated lower respiratory tract disease. Also Read: Moderna Scores FDA Approval For Its Second Product – Respiratory Syncytial Virus Vaccine. Abrysvo was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. While the company evaluated two doses, a single 120 µg dose of Abrysvo generated a strong neutralizing response against ...